AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31524645 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage only
Number of subjects: 120
Study 31524645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure only
Number of subjects: 120
Study 31524645 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage + Acupressure
Number of subjects: 120
Study 31524645 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 120
Study 31464642 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 1141
Study 31464642 — intervention group
Group type: COMPARATOR
Intervention: Control (bPI + emtricitabine/tenofovir disoproxil fumarate)
Number of subjects: 1141
Study 27701952 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on mirtazapine
Number of subjects: 39
Study 27701952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26036479 — intervention group
Group type: EXPERIMENTAL
Intervention: IGL-1
Number of subjects: 178
Study 26036479 — intervention group
Group type: COMPARATOR
Intervention: HTK
Number of subjects: 178
Study 23239694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated MRI
Number of subjects: 53
Study 23239694 — intervention group
Group type: COMPARATOR
Intervention: 4D-CT
Number of subjects: 53
Study 20170948 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril (20 mg) plus amlodipine (5 mg)
Number of subjects: 11506
Study 20170948 — intervention group
Group type: COMPARATOR
Intervention: benazepril (20 mg) plus hydrochlorothiazide (12.5 mg)
Number of subjects: 11506
Study 17526983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar plus bipolar recording (Uni-group; n=18)
Number of subjects: 36
Study 17526983 — intervention group
Group type: COMPARATOR
Intervention: Bipolar recording (Bi-group; n=18)
Number of subjects: 36
Study 17526983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar His bundle recordings in Uni-group
Number of subjects: 36
Study 16278188 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 123
Study 16278188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasse pillow
Number of subjects: 123
Study 16278188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary pillow
Number of subjects: 123
Study 12200762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber and vitamin combination therapy
Number of subjects: 119
Study 12200762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 10416312 — intervention group
Group type: COMPARATOR
Intervention: Normolipemics (Group A)
Number of subjects: 73
Study 10416312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypercholesterolemics (Group B)
Number of subjects: 73
Study 10416312 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypercholesterolemics (Group C)
Number of subjects: 73
Study 10416312 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglycerides (Group D)
Number of subjects: 73
Study 7589999 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg for 8 weeks
Number of subjects: 430
Study 7589999 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 b.i.d. for 8 weeks
Number of subjects: 430
Study 1688966 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 19
Study 1688966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7232006 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical tooth pulp stimulation at varying intensities (5 intensities)
Number of subjects: 30
Study 7232006 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical tooth pulp stimulation at varying intensities
Number of subjects: 30
Study 7232006 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (narcotic analgesic)
Number of subjects: 30
Study 31521532 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise on a stationary home-trainer, 30-45 min training three times per week for 6 months, enhanced with virtual reality software and real-life videos.
Number of subjects: 130
Study 31521532 — intervention group
Group type: COMPARATOR
Intervention: Stretching (active control group), 30-45 min training three times per week for 6 months.
Number of subjects: 130
Study 27314762 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera (systemic juice and topical gel) for 3 months
Number of subjects: 74
Study 27314762 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of hydrocortisone and hyaluronidase with antioxidant supplements for 6 weeks and 3 months respectively
Number of subjects: 74
Study 25110231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration at two target blood alcohol concentrations (40 and 80 mg%)
Number of subjects: 20
Study 25110231 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 20
Study 25110231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration
Number of subjects: 20
Study 25043153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg twice a day and dexamethasone (dex)
Number of subjects: 430
Study 25043153 — intervention group
Group type: COMPARATOR
Intervention: Placebo and dexamethasone (dex)
Number of subjects: 430
Study 21088895 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM)
Number of subjects: 18
Study 21088895 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial substitution of SBM with Streblus asper Lour foliage
Number of subjects: 18
Study 21088895 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial substitution of SBM with Leucaena (Leucaena leucocephala) foliage
Number of subjects: 18
Study 19680667 — intervention group
Group type: EXPERIMENTAL
Intervention: ASARP
Number of subjects: 38
Study 19680667 — intervention group
Group type: COMPARATOR
Intervention: PSARP
Number of subjects: 38
Study 18068514 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (0, 10, 40, 150, or 300 mg orally once a day for 28 days)
Number of subjects: 50
Study 18068514 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (150 mg once a day for 10 days)
Number of subjects: 50
Study 18068514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15885163 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 0
Study 15885163 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 12196048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 62
Study 12196048 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal placebo (ITP)
Number of subjects: 62
Study 12196048 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) injections of morphine every 4 hours as needed
Number of subjects: 62
Study 9484732 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (intravenous epirubicin hydrochloride: 8 doses of 40 mg/m2 each at 6-week intervals; transarterial chemotherapy: 3 courses with a maximum dose of 20 mL each at 2-month intervals)
Number of subjects: 66
Study 9484732 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control group)
Number of subjects: 66
Study 8548573 — intervention group
Group type: EXPERIMENTAL
Intervention: Three levels of pressure support systems used in association with a risk assessment tool during phase two of the study.
Number of subjects: 327
Study 8548573 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Norton scoring system used for risk assessment.
Number of subjects: 327
Study 2505715 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once a day)
Number of subjects: 165
Study 2505715 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg b.d.)
Number of subjects: 165
Study 2505715 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg once a day)
Number of subjects: 165
Study 2505715 — intervention group
Group type: COMPARATOR
Intervention: Combined hydrochlorothiazide + amiloride (50 mg + 5 mg once a day)
Number of subjects: 165
Study 2505715 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once a day) with diuretic
Number of subjects: 165
Study 2505715 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg b.d.) with diuretic
Number of subjects: 165
Study 2505715 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once a day) with atenolol
Number of subjects: 165
Study 2505715 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg once a day) with diuretic
Number of subjects: 165
Study 2505715 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once a day) with beta-blocker
Number of subjects: 165
Study 2505715 — intervention group
Group type: COMPARATOR
Intervention: Combined hydrochlorothiazide + amiloride (50 mg + 5 mg once a day) with beta-blocker
Number of subjects: 165
Study 916947 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-Dihydergot
Number of subjects: 2136
Study 916947 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 2136
Study 916947 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic-acid (ASS)
Number of subjects: 2136
Study 916947 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight dextran
Number of subjects: 2136
Study 916947 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine
Number of subjects: 2136
Study 30896659 — intervention group
Group type: COMPARATOR
Intervention: Microneedling and 660 nm red laser photobiomodulation sham
Number of subjects: 66
Study 30896659 — intervention group
Group type: COMPARATOR
Intervention: 660 nm red laser photobiomodulation and microneedling sham
Number of subjects: 66
Study 30896659 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling and 660 nm red laser photobiomodulation
Number of subjects: 66
Study 29683854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 49
Study 29683854 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 49
Study 27349901 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 811283 (Aurora B kinase inhibitor) administered via 24‐h infusion on Days 1 and 15 of a 4‐week cycle (schedule A) or Day 1 of a 3‐week cycle (schedule B)
Number of subjects: 121
Study 27349901 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 811283 (Aurora B kinase inhibitor)
Number of subjects: 121
Study 24687764 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational documentary video
Number of subjects: 202
Study 24687764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 202
Study 22379336 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (EEN)
Number of subjects: 38
Study 22379336 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 38
Study 18805649 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning radiotherapy (RT) (8‐10 AM)
Number of subjects: 216
Study 18805649 — intervention group
Group type: COMPARATOR
Intervention: Afternoon radiotherapy (RT) (4‐6 PM)
Number of subjects: 216
Study 18805649 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning RT
Number of subjects: 216
Study 18805649 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning RT (66‐70 Gy in 33‐35 fractions)
Number of subjects: 216
Study 18805649 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning RT (for smokers)
Number of subjects: 216
Study 18260939 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25-75 mg/day)
Number of subjects: 49
Study 18260939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spironolactone)
Number of subjects: 49
Study 16231621 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA circuits (n=20)
Number of subjects: 40
Study 16231621 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibited SMA patients (n=11)
Number of subjects: 40
Study 12116339 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated ICE with filgrastim and autologous stem cell support
Number of subjects: 11
Study 12116339 — intervention group
Group type: COMPARATOR
Intervention: Standard ICE chemotherapy
Number of subjects: 11
Study 9987705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 6
Study 7587900 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 155
Study 7587900 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide
Number of subjects: 155
Study 7587900 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofran (Glaxo)
Number of subjects: 155
Study 2187981 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal reactors (n = 58)
Number of subjects: 202
Study 2187981 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 55)
Number of subjects: 202
Study 2187981 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologic patients (n = 89)
Number of subjects: 202
Study 6773727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin therapy
Number of subjects: 48
Study 6773727 — intervention group
Group type: COMPARATOR
Intervention: High-dose insulin therapy
Number of subjects: 48
Study 30333270 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of DLBS1033 (3 x 490 mg)
Number of subjects: 2
Study 30333270 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of DLBS1033 (3 x 490 mg/day for 3 days)
Number of subjects: 2
Study 30333270 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety parameters (creatinine, prothrombin time, activated partial thromboplastin time, SGOT, SGPT)
Number of subjects: 2
Study 27078119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 40
Study 27078119 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus vancomycin (comparator)
Number of subjects: 40
Study 24450305 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (CFO)
Number of subjects: 154
Study 24450305 — intervention group
Group type: COMPARATOR
Intervention: Sham orthoses
Number of subjects: 154
Study 22752966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (10,000 IU per day for 3 months)
Number of subjects: 52
Study 22752966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20402381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy (8 mg/kg every 4 weeks)
Number of subjects: 0
Study 20402381 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 0
Study 18756880 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (5 mg Prednisolonacetate, anterior H‐inject, Winthorp) administered via parabulbar injections every day/five days
Number of subjects: 475
Study 18756880 — intervention group
Group type: COMPARATOR
Intervention: Regular polyvitamine therapy (Lutein, Beta Karoten, Vitamin E)
Number of subjects: 475
Study 15903378 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 60
Study 15903378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise (DY)
Number of subjects: 60
Study 15903378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise plus 3 drop jumps from 15-cm boxes (DYJ)
Number of subjects: 60
Study 15903378 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 12783161 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) with lactate-buffered replacement fluids for 8 hours
Number of subjects: 10
Study 12783161 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemofiltration (CVVH) with lactate-buffered replacement fluids for 8 hours
Number of subjects: 10
Study 10383377 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency angiography followed by revascularization (PTCA or CABG)
Number of subjects: 55
Study 10383377 — intervention group
Group type: COMPARATOR
Intervention: Initial medical management
Number of subjects: 55
Study 10383377 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry patients (not randomized)
Number of subjects: 55
Study 8786174 — intervention group
Group type: EXPERIMENTAL
Intervention: BK-F membrane (1.3 m2)
Number of subjects: 10
Study 8786174 — intervention group
Group type: COMPARATOR
Intervention: BK-P membrane (1.6 m2)
Number of subjects: 10
Study 8786174 — intervention group
Group type: COMPARATOR
Intervention: Cellulose acetate (CA, 1.3 m2)
Number of subjects: 10
Study 1852664 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (100 mg twice daily)
Number of subjects: 19
Study 1852664 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 19
Study 1852664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6341410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 87
Study 6341410 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 87
Study 6341410 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 87
Study 30972712 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 7794
Study 30972712 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-event patients with ≥ 180 days of warfarin exposure)
Number of subjects: 7794
Study 28792105 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTNS plus 20 mg trospium chloride daily
Number of subjects: 30
Study 28792105 — intervention group
Group type: COMPARATOR
Intervention: TPTNS alone
Number of subjects: 30
Study 26807631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of rtPA, perfluoropropane (C3F8) gas, and bevacizumab (n = 12)
Number of subjects: 24
Study 26807631 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with subretinal rtPA administration, intravitreal C3F8 gas, and bevacizumab (n = 12)
Number of subjects: 24
Study 24293332 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-compartment compliance aids (MCAs)
Number of subjects: 54
Study 24293332 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients refusing MCA)
Number of subjects: 54
Study 21198965 — intervention group
Group type: EXPERIMENTAL
Intervention: High biotin diet (2000 μg/kg)
Number of subjects: 116
Study 21198965 — intervention group
Group type: EXPERIMENTAL
Intervention: High Zn diet (150 mg/kg)
Number of subjects: 116
Study 21198965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannan-oligosaccharides (MOS) diet (1%)
Number of subjects: 116
Study 21198965 — intervention group
Group type: COMPARATOR
Intervention: Control diet (300 μg biotin and 50 mg Zn/kg)
Number of subjects: 116
Study 21198965 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet litter exposure (27% DM for 8 h daily)
Number of subjects: 116
Study 21135293 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (1 to 3 mg/h for 48 hours)
Number of subjects: 316
Study 21135293 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (15 mg/kg daily, max 1000 mg for 48 hours)
Number of subjects: 316
Study 17893462 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of intracranial venous thrombosis in parturients after regional anesthesia
Number of subjects: 0
Study 16301237 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with TIVA (fentanyl and propofol)
Number of subjects: 0
Study 16301237 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with F-P-I (fentanyl, thiopental, and isoflurane)
Number of subjects: 0
Study 16301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal block with 5 mg of 0.5% bupivacaine (LDS)
Number of subjects: 0
Study 16301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal block with 2.5 mg of 0.5% bupivacaine plus 25 mug of fentanyl (SDS)
Number of subjects: 0
Study 16301237 — intervention group
Group type: COMPARATOR
Intervention: Spinal block with 2.5 mg of bupivacaine plus 25 mug of fentanyl (SDS)
Number of subjects: 0
Study 11988605 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual hemifield stimulation of the unaffected side of stroke patients
Number of subjects: 14
Study 11988605 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual hemifield stimulation of the hemianopic side
Number of subjects: 14
Study 11988605 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 14
Study 9816887 — intervention group
Group type: EXPERIMENTAL
Intervention: LP positive patients (group I, 30 patients)
Number of subjects: 56
Study 9816887 — intervention group
Group type: COMPARATOR
Intervention: LP negative patients (group II, 26 patients)
Number of subjects: 56
Study 7621007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem treatment
Number of subjects: 13
Study 7621007 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 13
Study 7621007 — intervention group
Group type: COMPARATOR
Intervention: Control group with ischemic cardiopathy (no calcium antagonists)
Number of subjects: 13
Study 7621007 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 13
Study 2658574 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric amphotericin B
Number of subjects: 132
Study 2658574 — intervention group
Group type: COMPARATOR
Intervention: No empiric antifungal therapy (control)
Number of subjects: 132
Study 5302329 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency whole-cell cholera vaccine
Number of subjects: 0
Study 5302329 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Ogawa antigen (lipopolysaccharide)
Number of subjects: 0
Study 5302329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine
Number of subjects: 0
Study 31043161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plant sterols (PS) and omega‐3 fatty acids
Number of subjects: 200
Study 31043161 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega‐3 fatty acids alone
Number of subjects: 200
Study 31043161 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) alone
Number of subjects: 200
Study 31043161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy bean powder plus placebo capsules)
Number of subjects: 200
Study 27749740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica gel
Number of subjects: 82
Study 27749740 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogen cream (CEE)
Number of subjects: 82
Study 25533593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 0